Bulk Pharmaceutical API Sources for AMIFOSTINE

Bulk Pharmaceutical API Sources for AMIFOSTINE

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-003-666-801
Hangzhou APIChem Technology		AC-1126
Amadis Chemical		A814662
AKos Consulting & Solutions		AKOS015895196
Finetech Industry Limited		FT-0622272

Bulk Active Pharmaceutical Ingredient (API) Sources for Amifostine

Last updated: July 29, 2025

Introduction

Amifostine, marketed under the brand name Ethyol, is a cytoprotective agent primarily used to mitigate the nephrotoxic effects of cisplatin in cancer chemotherapy and to reduce xerostomia in head and neck cancer patients undergoing radiotherapy. As an important pharmaceutical compound, its sourcing in bulk API form is critical for pharmaceutical manufacturers, supplying a reliable, high-quality product essential for patient safety and regulatory compliance.

The global API supply chain for amifostine is a complex network involving multiple regions, manufacturers, and regulatory considerations. This article provides a comprehensive overview of key API sources, global manufacturing landscapes, and critical factors influencing procurement strategies.

---

Global API Manufacturing Landscape for Amifostine

Leading API Manufacturers

The primary manufacturers of amifostine API are predominantly located in India and China. These regions dominate the global pharmaceutical ingredient supply due to cost advantages, manufacturing expertise, and established export infrastructure.

• India: India-based pharmaceutical companies such as Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, and Aarti Industries have developed capabilities in synthesizing amifostine API. Their manufacturing facilities typically comply with Good Manufacturing Practices (GMP) and hold certifications from international bodies like the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S).

• China: Several Chinese API manufacturers, including Zhejiang Huahai Pharmaceutical, North China Pharmaceutical Group Corporation (China Resources), and others, produce amifostine API for export. These manufacturers often leverage cost efficiencies and large-scale production capabilities.

Key Attributes of Leading Suppliers

• Quality Assurance: Certified facilities conforming to GMP standards, with rigorous quality control protocols.
• Certifications: International certifications such as ISO 9001, ISO 14001, and CE mark certifications facilitate export to regulated markets.
• R&D Capability: Some manufacturers possess in-house R&D to optimize synthesis routes and ensure consistent API quality.
• Supply Reliability: Long-standing relationships with global pharmaceutical companies and regulatory authorities ensure steady supply chains.

---

Supply Chain Dynamics and Sourcing Considerations

Regulatory Compliance and Quality Standards

API purchasing in this sector demands strict compliance with regulatory standards like the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regional authorities. Suppliers with validated manufacturing processes, dossier documentation, and consistent batch-to-batch quality are preferred.

Pricing and Cost Factors

Cost competitiveness in China and India remains pivotal. Manufacturers with advanced economies of scale can offer competitive pricing, but buyers must scrutinize quality assurances to avoid substandard products that could compromise safety.

Supply Chain Risks

Dependence on suppliers from specific regions can increase risks related to geopolitical issues, trade restrictions, or supply disruptions due to unforeseen circumstances such as the COVID-19 pandemic. Diversification across multiple suppliers and regions mitigates these risks.

---

Major API Suppliers and Distributors

Supplier/Manufacturer	Region	Certifications	Note
Sun Pharmaceutical Industries	India	GMP, ISO 9001, WHO-GMP	Known for broad API portfolio and reliable supply
Dr. Reddy’s Laboratories	India	GMP, ISO 9001	Significant global presence, quality adherence
Aarti Industries	India	GMP, ISO 9001	Focus on high-quality APIs for export markets
Zhejiang Huahai Pharmaceutical	China	GMP, ISO 9001	Large-scale producer with global exports
North China Pharmaceutical Group	China	GMP	Emerging supplier with increasing market share

Additionally, large API distributors such as Win Health Pharma, GSK Bulk, and Famar source amifostine API from these manufacturers and serve as intermediaries to pharmaceutical firms worldwide.

---

Quality and Regulatory Due Diligence

Due diligence extends beyond certification. Buyers should review:

• Batch-release testing reports
• Certificate of Analysis (CoA)
• Validated manufacturing sites
• Stability data for each batch
• Prior regulatory inspection reports (for supplier site)

Engagement with suppliers holding recent Good Manufacturing Practice (GMP) inspections is advisable to ensure ongoing compliance.

---

Emerging Trends in API Sourcing for Amifostine

• Localization and Nearshoring: Some pharmaceutical companies are exploring regional manufacturing hubs to reduce dependency on Asian suppliers.
• API Synthesis Optimization: Investments into greener, cost-efficient synthetic routes enhance supply sustainability.
• Supply Chain Digitization: Platforms like GlobalCDN facilitate real-time transparency, reducing lead times.

---

Regulatory and Licensing Considerations

API manufacturers must possess relevant manufacturing licenses, and exporters must navigate regional export regulations, including compliance with the Drug Master File (DMF) submissions to agencies like the FDA or EMA. Buyers should validate that suppliers’ documentation aligns with the intended use.

---

Conclusion

The primary bulk API sources for amifostine are concentrated in India and China, with reputable manufacturers offering GMP-compliant products suitable for global pharmaceutical markets. Strategic sourcing involves balancing cost, quality, supply security, and regulatory compliance. While regional diversification and technological advancements mitigate risks, ongoing due diligence remains essential to ensure supply integrity and product quality.

---

Key Takeaways

1. Major Suppliers: India and China dominate amifostine API production, with established manufacturers adhering to international GMP standards.
2. Regulatory Compliance: Prioritize suppliers with current certifications, validated processes, and transparent quality documentation.
3. Supply Chain Resilience: Diversify sources across multiple regions to mitigate geopolitical and logistical risks.
4. Cost vs. Quality: While cost advantages are significant, uncompromising quality ensures regulatory compliance and patient safety.
5. Future Outlook: Emerging trends around local manufacturing and process innovation are set to shape supply dynamics.

---

FAQs

1. What are the primary regions producing amifostine API?
India and China are the main regions, with numerous GMP-certified manufacturers exporting globally.

2. How can I verify the quality of amifostine API suppliers?
Review certification documents (GMP, ISO), batch-release reports, certificates of analysis, and conduct audits if feasible.

3. What regulatory considerations are critical when sourcing amifostine API?
Ensure suppliers hold valid manufacturing licenses, comply with regional regulations, and have up-to-date DMFs submitted to authorities like FDA or EMA.

4. Are there alternative sources for amifostine API outside Asia?
While primarily sourced from India and China, some European and North American manufacturers are emerging, but cost and capacity constraints limit their prevalence.

5. How does supply chain risk impact API sourcing decisions?
Dependence on certain regions can introduce vulnerability due to geopolitical issues, trade barriers, or global crises, necessitating supplier diversification.

---

Sources

1. [1] "API Manufacturers in India," Indian Pharmaceutical Alliance, 2022.
2. [2] "Chinese API Industry Overview," China Chemical & Pharmaceutical Association, 2022.
3. [3] U.S. FDA Drug Master Files Database.
4. [4] Pharmeasy: Global API Market Report, 2022.
5. [5] "Regulatory Guidelines for API Imports," EMA, 2022.